As mentioned above, patients with MSS, RAS and BRAF wild-type mCRC and a primary tumor located in the left colon are considered suitable candidates for first-line anti-EGFR treatment in combination with chemotherapy [4,31,32,33,85,86,87]. The gene discussed is EGFR; the disease is neoplasm.